FDA Approves RHA Redensity Eye for Infraorbital Volume Deficiencies
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
FDA approves RHA Redensity Eye for correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults ages 22 and older.
Data presented at the Science of Skin Summit indicate topical regimens and treatments yield visible improvements in laxity, crepiness, and perceived age among individuals taking GLP-1 therapies.